Suppr超能文献

安全开处阿片类药物工具(SPOT):一种用于姑息治疗和生命终末期阿片类药物转换的新型临床决策支持数字健康平台:单中心试点研究。

The Safer Prescription of Opioids Tool (SPOT): A Novel Clinical Decision Support Digital Health Platform for Opioid Conversion in Palliative and End of Life Care-A Single-Centre Pilot Study.

机构信息

Medical School, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK.

NHS Tayside Ninewells Hospital, Dundee DD1 9SY, UK.

出版信息

Int J Environ Res Public Health. 2019 May 31;16(11):1926. doi: 10.3390/ijerph16111926.

Abstract

Opioid errors are a leading cause of patient harm. Active failures in opioid dose conversion can contribute to error. Conversion is complex and is currently performed manually using tables of approximate equivalence. Apps that offer opioid dose double-checking are available but there are concerns about their accuracy and clinical validation. This study evaluated a novel opioid dose conversion app, The Safer Prescription of Opioids Tool (SPOT), a CE-marked Class I medical device, as a clinician decision support (CDS) platform. This single-centre prospective clinical utility pilot study followed a mixed methods design. Prescribers completed an initial survey exploring their current opioid prescribing practice. Thereafter prescribers used SPOT for opioid dosage conversions in parallel to their usual clinical practice, then evaluated SPOT through a survey and focus group. SPOT matched the Gold Standard result in 258 of 268 (96.3%) calculations. The 10 instances (3.7%) when SPOT did not match were due to a rounding error. Users had a statistically significant increase in confidence in prescribing opioids after using SPOT. Focus group feedback highlighted benefits in Quality Improvement and Safety when using SPOT. SPOT is a safe, reliable and validated CDS that has potential to reduce harms from opioid dosing errors.

摘要

阿片类药物错误是导致患者伤害的主要原因。阿片类药物剂量换算中的主动失效可能导致错误。转换很复杂,目前是使用近似等效性的表格手动进行的。提供阿片类药物剂量双重检查的应用程序可用,但人们对其准确性和临床验证存在担忧。这项研究评估了一种新型阿片类药物剂量转换应用程序,即安全开处阿片类药物工具 (SPOT),这是一种获得 CE 标志的 I 类医疗器械,作为临床医生决策支持 (CDS) 平台。这项单中心前瞻性临床实用性试点研究采用了混合方法设计。开处方者完成了一项初步调查,探讨了他们目前的阿片类药物处方实践。此后,开处方者在常规临床实践中同时使用 SPOT 进行阿片类药物剂量转换,然后通过调查和焦点小组评估 SPOT。SPOT 在 268 次计算中有 258 次(96.3%)与黄金标准结果匹配。10 次(3.7%)不匹配是由于舍入误差。用户在使用 SPOT 后对开处阿片类药物的信心有统计学显著提高。焦点小组的反馈强调了使用 SPOT 时在质量改进和安全性方面的好处。SPOT 是一种安全、可靠且经过验证的 CDS,具有减少阿片类药物剂量错误造成伤害的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1f/6612362/e1fd7129cead/ijerph-16-01926-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验